SCHEMBL9930381

SCHEMBL9930381

CCCS(=O)(=O)Nc1ccc(Cl)c(C(N)=O)c1Cl

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 17/20 0.54
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
BMPR1B O00238 1/20 0.39
PLK4 O00444 1/20 0.39
PIR O00625 1/20 0.39
AURKA O14965 1/20 0.39
DCLK1 O15075 1/20 0.39
EPHB6 O15197 1/20 0.39
RIPK2 O43353 1/20 0.39
STK16 O75716 1/20 0.39
OXSR1 O95747 1/20 0.39
MAP4K4 O95819 1/20 0.39
ABL1 P00519 1/20 0.39
RAF1 P04049 1/20 0.39
LCK P06239 1/20 0.39
FYN P06241 1/20 0.39
FES P07332 1/20 0.39
CSF1R P07333 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL913580 0.87 BRAF (0.55) BRAFCYP3A4CYP2C9CYP2C19
SCHEMBL9930598 0.86 BRAF (0.55) BRAFCYP3A4CYP2C9CYP2C19BMPR1B
SCHEMBL9930989 0.86 CYP3A4 (0.51) BRAFCYP3A4CYP2C9CYP2C19BMPR1B
SCHEMBL9931343 0.84 BRAF (0.43) BRAFCYP2C9RAF1
SCHEMBL12075936 0.83 BRAF (0.45) BRAFCYP3A4CYP2C9CYP2C19
SCHEMBL12075999 0.83 BRAF (0.43) BRAFCYP3A4CYP2C9CYP2C19BMPR1B
SCHEMBL1461774 0.80 BRAF (0.45) BRAFCYP3A4CYP2C9CYP2C19
SCHEMBL6795655 0.80 BRAF (0.48) BRAF
SCHEMBL13705593 0.78 BRAF (0.47) BRAFCYP3A4CYP2C9CYP2C19
SCHEMBL9931267 0.78 ALDH1A1 (0.50) BRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130018033-A1 RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF ARRAY BIOPHARMA INC. (US) 2013-01-17 US claimed
US-20130018033-A1 RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF ARRAY BIOPHARMA INC. (US) 2013-01-17 US disclosed
EP-2470538-A1 RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF Array Biopharma, Inc. (US) 2012-07-04 EP disclosed
US-20120157439-A1 RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2012-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130018033-A1 RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF BRAF, RAF1, ARAF BRAF 1/4885CYP3A4 2785/4885CYP2C9 2926/4885
US-20120157439-A1 RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF BRAF, RAF1, ARAF BRAF 1/4885CYP3A4 2785/4885CYP2C9 2926/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.